Galectin Therapeutics Chief Medical Officer Jamil Khurram Reports Disposal of Common Shares

Reuters
2025.11.14 21:04
portai
I'm PortAI, I can summarize articles.

Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., reported a disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system, with Ref. ID: 0001133416-25-000054, dated November 14, 2025.

Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001133416-25-000054), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer